ResultsIQ

ResultsIQ › Latest results › Aarti Pharmalabs Limited

Aarti Pharmalabs Limited Q2 FY26 results deck summary

NSE: AARTIPHARM · BSE: 543748

Results deck of 11 Nov 2025, summarised by AI from the filing.

Xanthine derivatives segment operated at incremental capacity with higher share of beverages customers, yielding better margins.

Key takeaways

  1. Driver Xanthine derivatives segment operated at incremental capacity with higher share of beverages customers, yielding better margins.
  2. Risk API business witnessed margin pressure and sales mix skewed towards lower margin APIs, leading to weaker profitability.

Original filing on BSE

Aarti Pharmalabs Limited Q1 FY27 results

As filed: Revenue ₹536 cr (+39% year on year), EBITDA ₹136 cr (+43% year on year), PAT ₹76.1 cr (+52% year on year), EBITDA margin 25.4% (+79 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹583 cr (+3% year on year), EBITDA ₹113 cr (−23% year on year), PAT ₹61.1 cr (−31% year on year), EBITDA margin 19.4% (−665 bps). Score 42 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 665 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −2.0% in 30 days (Nifty 500: +2.8%).
  • Q3 FY26: Revenue ₹432 cr (−20% year on year), EBITDA ₹102 cr (−21% year on year), PAT ₹48.0 cr (−35% year on year), EBITDA margin 23.7% (−31 bps). Score 22 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 31 bps year on year. Share price after the results: −14.3% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹418 cr (−9% year on year), EBITDA ₹75.0 cr (−21% year on year), PAT ₹28.0 cr (−49% year on year), EBITDA margin 17.9% (−280 bps). Score 17 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 280 bps year on year. Profit fell 44% from last quarter. Share price after the results: −16.2% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹386 cr (−30% year on year), EBITDA ₹95.0 cr (−2% year on year), PAT ₹50.0 cr (−9% year on year), EBITDA margin 24.6% (+713 bps). Score 19 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin rose 713 bps year on year. Revenue fell 32% from last quarter. Share price after the results: +6.6% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹564 cr (+11% year on year), EBITDA ₹147 cr (+25% year on year), PAT ₹88.0 cr (+35% year on year), EBITDA margin 26.1% (+274 bps). Score 51 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was above it. EBITDA margin rose 274 bps year on year. Share price after the results: +19.0% in 30 days (Nifty 500: +7.6%).
  • Q3 FY25: Revenue ₹538 cr (+20% year on year), EBITDA ₹129 cr (+34% year on year), PAT ₹74.0 cr (+40% year on year), EBITDA margin 24.0% (+260 bps). Score 78 of 100, Above trend. EBITDA margin rose 260 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹458 cr (+4% year on year), EBITDA ₹95.0 cr (+8% year on year), PAT ₹55.0 cr (+6% year on year), EBITDA margin 20.7% (+74 bps). Score 43 of 100, In line with trend. EBITDA margin rose 74 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 17% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Aarti Pharmalabs Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.